1、MILLIMAN REPORT The impact of medication adherence on total healthcare costs for commercially insured patients A current perspective for patients with diabetes,hypertension,and hyperlipidemia May 2025 Michael T.Hunter,PharmD,Principal and Pharmacy Management Consultant Kali Schweitzer,PharmD,Pharmac

2、y Management Consultant Jay Blomquist,Senior Pharmacy Contracting Management Consultant Mat Khan,Senior Pharmacy Management Consultant Pepper Huang,Actuarial Manager MILLIMAN REPORT Table of contents I.EXECUTIVE SUMMARY.1 II.INTRODUCTION.2 RISING HEALTHCARE SPEND AND THE ROLE OF ADHERENCE.2 ADDRESSI

3、NG THE NEED FOR CURRENT ADHERENCE RESEARCH.3 III.RESULTS.5 DIABETES RESULTS.6 HYPERTENSION RESULTS.8 HYPERLIPIDEMIA RESULTS.8 IV.DISCUSSION.9 LIMITATIONS.10 V.METHODOLOGY.12 DATA SOURCES.12 STUDY POPULATION.12 CALCULATING ADHERENCE.12 STRATIFICATION AND STATISTICS.13 APPENDIX A:DRUG CLASSES USED FOR

4、 PATIENT IDENTIFICATION AND CLAIMS ANALYSIS.14 APPENDIX B:ICD-10 DIAGNOSTIC INDICATORS USED FOR PATIENT IDENTIFICATION AND CLAIMS ANALYSIS.14 APPENDIX C:EXPANDED RESULTS FOR ALL MARA CXXPLN RISK SCORES.15 MILLIMAN REPORT The impact of medication adherence on total 1 healthcare costs for commercially

5、 insured patients May 2025 I.Executive Summary We performed an analysis of medication adherence in commercially insured patients aged 18 to 64 with diabetes,hypertension,or hyperlipidemia,and observed a stronger relationship between medication adherence and lower healthcare costs for patients with h

6、igh risk scores.These results suggest that employers and healthcare providers may benefit from stratifying patients by imputing health risk scores into their claims data.This process will improve insights into the relationship between adherence interventions and overall healthcare costs.Healthcare e